Rice Hall James & Associates LLC Sells 363 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Rice Hall James & Associates LLC cut its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 0.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 48,140 shares of the medical equipment provider’s stock after selling 363 shares during the period. Rice Hall James & Associates LLC owned about 0.07% of Lantheus worth $4,307,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in LNTH. Groupama Asset Managment bought a new stake in Lantheus during the third quarter worth approximately $439,000. Swedbank AB increased its position in shares of Lantheus by 53.3% during the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock valued at $99,054,000 after purchasing an additional 385,000 shares during the last quarter. Janus Henderson Group PLC raised its holdings in Lantheus by 7.7% during the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock valued at $393,844,000 after buying an additional 257,022 shares during the period. Massachusetts Financial Services Co. MA purchased a new stake in Lantheus during the 3rd quarter valued at $25,955,000. Finally, Point72 DIFC Ltd bought a new stake in Lantheus in the third quarter worth $23,001,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on LNTH. The Goldman Sachs Group began coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. Truist Financial reissued a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, JMP Securities reiterated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Lantheus presently has an average rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $79.94 on Tuesday. Lantheus Holdings, Inc. has a 52-week low of $56.06 and a 52-week high of $126.89. The firm has a market capitalization of $5.56 billion, a price-to-earnings ratio of 13.30 and a beta of 0.44. The stock has a 50 day moving average price of $91.17 and a 200 day moving average price of $97.53.

Insider Transactions at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.50% of the company’s stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.